Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL470322 | 0.90 | PDE4A (0.39) | CYP3A4TP53 | |
| SCHEMBL461591 | 0.84 | GRM5 (0.37) | PIN1PKMTP53THRB | |
| SCHEMBL10175470 | 0.83 | CYP3A4 (0.39) | CYP3A4NR1I2THRB | |
| SCHEMBL462476 | 0.82 | NR1I2 (0.51) | CYP3A4NR1I2TP53 | |
| SCHEMBL463413 | 0.82 | KDM4E (0.39) | CYP3A4PSIP1PIN1TP53THRB | |
| SCHEMBL10175062 | 0.79 | PDE4A (0.41) | TP53 | |
| SCHEMBL461161 | 0.79 | PDE4A (0.41) | TP53 | |
| SCHEMBL461824 | 0.78 | NR1I2 (0.70) | CYP3A4NR1I2PSIP1 | |
| SCHEMBL461443 | 0.78 | NR1I2 (0.70) | CYP3A4NR1I2PSIP1 | |
| SCHEMBL15227172 | 0.76 | NR1I2 (0.56) | CYP3A4NR1I2PSIP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633200-B2 | Inhibitors of human immunodeficiency virus replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-21 | — | — | US | disclosed |
| EP-2614064-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | Bristol-Myers Squibb Company (US) | 2013-07-17 | — | — | EP | disclosed |
| US-20120225888-A1 | Inhibitors of Human Immunodeficiency Virus Replication | BRISTOL-MYERS SQUIBB COMPANY | 2012-09-06 | — | — | US | disclosed |
| WO-2012033735-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225888-A1 | Inhibitors of Human Immunodeficiency Virus Replication | EIF2AK2, RTF2, MAVS | CYP3A4 1719/4885NR1I2 3085/4885PSIP1 1676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.